Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

10 Aug 2015

Abstract excerpt

Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of these drugs is limited because of occurrence of inherent or acquired therapy resistances during the treatment. Thus, identification of new molecular targets is urgently required to improve current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26257066
DOI: 10.1038/onc.2015.292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancerPMID 26257066Read ↗

AR Signaling and the PI3K Pathway in Prostate CancerSemantic proximity Read ↗

Overexpression of AR‐regulated lncRNA TMPO‐AS1 correlates with tumor progression and poor prognosis in prostate cancerSemantic proximity Read ↗

G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer.Semantic proximity Read ↗

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancerSemantic proximity Read ↗

Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate CancerSemantic proximity Read ↗

PIAS family in cancer: from basic mechanisms to clinical applicationsSemantic proximity Read ↗

Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signalingSemantic proximity Read ↗

The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cellsSemantic proximity Read ↗

Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancerSemantic proximity Read ↗

MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancerSemantic proximity Read ↗

The androgen receptor—lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cellsSemantic proximity Read ↗

A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.